Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T05:36:10.846Z Has data issue: false hasContentIssue false

Ab initio molecular dynamics studies on HIV-1 reverse transcriptase triphosphate binding site: Implications for nucleoside–analog drug resistance

Published online by Cambridge University Press:  10 February 2001

FRANK ALBER
Affiliation:
International School for Advanced Studies (SISSA) and Istituto Nazionale di Fisica della Materia (INFM), Via Beirut 2-4, 34014, Trieste, Italy
PAOLO CARLONI
Affiliation:
International School for Advanced Studies (SISSA) and Istituto Nazionale di Fisica della Materia (INFM), Via Beirut 2-4, 34014, Trieste, Italy International Centre for Genetic Engineering and Biotechnology, AREA Science Park, Padriciano 99, 34012, Trieste, Italy
Get access

Abstract

Quantum-chemical methods are used to shed light on the functional role of residues involved in the resistance of HIV-1 reverse transcriptase against nucleoside-analog drugs. Ab initio molecular dynamics simulations are carried out for models representing the adduct between the triphosphate substrate and the nucleoside binding site. The triphosphate is considered either deprotonated or protonated at the γ-position. Although the protonated form already experiences large rearrangements in the ps time scale, the fully deprotonated state exhibits a previously unrecognized low-barrier hydrogen bond between Lys65 and γ-phosphate. Absence of this interaction in Lys65→Arg HIV-1 RT might play a prominent role in the resistance of this mutant for nucleoside analogs (Gu Z et al., 1994b, Antimicrob Agents Chemother 38:275–281; Zhang D et al., 1994, Antimicrob Agents Chemother 38:282–287). Water molecules present in the active site, not detected in the X-ray structure, form a complex H-bond network. Among these waters, one may be crucial for substrate recognition as it bridges Gln151 and Arg72 with the β-phosphate. Absence of this stabilizing interaction in Gln151→Met HIV-1 RT mutant may be a key factor for the known drug resistance of this mutant toward dideoxy-type drugs and AZT (Shirasaka T et al., 1995, Proc Natl Acad Sci USA 92:2398–2402; Iversen AK et al., 1996, J Virol 70:1086–1090).

Type
Research Article
Copyright
© 2000 The Protein Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)